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A B S T R A C T
Kaposi’s sarcoma (KS) usually presents in HIV-infected patients with cutaneous lesions that may
advance to extensive visceral disease. There have been only a few documented cases in which the initial
presentation of Kaposi’s sarcoma involved the bronchopulmonary system. We describe a newly
diagnosed patient who presented with pulmonary KS as his initial presentation of the disease. Our report
is intended to increase clinicians’ awareness that pulmonary Kaposi’s sarcoma should be considered in
HIV-infected patients who present with respiratory symptoms, even if they do not manifest the typical
mucocutaneous manifestations of KS or have low CD4 counts. Early diagnosis and therapy are essential
in improving outcomes as this condition carries a high mortality.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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HIV-related Kaposi’s sarcoma (KS) is a low grade vascular tumor
associated with human herpesvirus 8 (HHV-8), usually seen in
patients with low CD4 cell counts. Kaposi’s sarcoma (KS) presents
with mucocutaneous disease in 80–90% of cases, but may advance
to extensive visceral disease [1]. In rare instances, early presenta-
tion may manifest with only respiratory signs and symptoms. We
describe a patient with bronchopulmonary KS as the initial
presentation of HIV infection.
Case presentation
A 29-year-old man with no signiﬁcant past medical or sexual
history other than having sex with men presented to the
emergency department with a three-month history of increasing
lower extremity edema. The patient was noted to have a warm,
erythematous area on his right tibia with slight serous drainage
consistent with a cellulitis or early abscess. Cultures of the lesion
grew methicillin-susceptible Staphylococcus aureus. His HIV* Corresponding author at: 185 South Orange Avenue, Newark, NJ 07103,
United States. Tel.: +1 973 972 6056.
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3.0/).antibody test was positive; CD4 count was 325 cells/mm3 and
plasma HIV RNA viral load was 518,645 copies/ml. The patient was
treated with a 10-day course of oral trimethoprim-sulfamethoxa-
zole and cephalexin. He returned one month later with complaints
of shortness of breath, dry cough, and swelling of his lower
extremities, scrotum and penis. On examination, he was febrile
and had diffuse adenopathy with palpable anterior and posterior
cervical, submental, supraclavicular and axillary lymph nodes and
extensive edema involving the bilateral lower extremities. No
other mucosal or skin ﬁndings were present. Diffuse interstitial
inﬁltrates and basilar alveolar opacities were present on chest
radiographs. Computed tomography (CT) scan of the chest,
abdomen and pelvis demonstrated diffuse anasarca and ill-deﬁned
nodular opacities in both lung bases (Fig. 1).
Antiretroviral therapy (ART) with darunavir, ritonavir and
raltegravir was initiated. He was treated empirically with
intravenous trimethoprim-sulfamethoxazole for possible pneu-
mocystis pneumonia and azithromycin and ceftriaxone for
possible community acquired pneumonia. The following day his
respiratory status deteriorated requiring transfer to the intensive
care unit. He underwent bronchoscopy with transbronchial biopsy
of the right lower lobe and left lower lobe. No gross endobronchial
lesions were noted. The bronchial biopsy showed areas of
interstitial spindle cell proliferation extending into alveolar septae
(Figs. 2 and 3). Immunoperoxidase staining for human herpese under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. Computed tomography scan of the chest. CT of the chest showing anasarca,
pulmonary edema, small bilateral pleural effusions, and ill-deﬁned nodular
opacities in both lung bases.
Fig. 2. Histopathology. Scanning power micrograph of the bronchial biopsy showing
the pulmonary parenchyma with proliferation of spindle cells (arrow) forming cleft
like spaces, widening the interstitium and extending to the alveolar septae (H&E
stain, 40 magniﬁcation).
Fig. 3. Intermediate power micrograph showing an area of spindle cell proliferation
seen in Fig. 2. The arrow points to a cleft like space lined by spindle cells (H&E stain,
100 magniﬁcation).
Fig. 4. Intermediate power photomicrograph of the bronchial biopsy stained by the
immunoperoxidase method for human herpes virus-8 (HHV8) in an area of spindle
cell proliferation. The brown stained nuclei (arrow) represent a positive reaction
diagnostic of involvement by Kaposi’s sarcoma (HHV-8 immunoperoxidase stain,
100 magniﬁcation).
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ing spindle cells, conﬁrming the diagnosis of pulmonary Kaposi’s
sarcoma (Fig. 4). The patient was evaluated by our oncology service
but was considered too ill to tolerate radiation or chemotherapy for
treatment of KS. He was continued on ART, but developed
progressive symptoms and expired two weeks after diagnosis.
Discussion
Pulmonary KS has been reported to occur in 6–32% of HIV-
infected patients with cutaneous disease, with ages ranging from
22 to 71 years; less than 5% present with pulmonary KS as theinitial manifestation [13]. KS is more common in men who have
sex with men, but cases have been reported in women as well. HIV-
infected patients with pulmonary KS may be asymptomatic or
present with shortness of breath, fever, cough, chest pain, or
hemoptysis. Pulmonary KS can involve the lung parenchyma,
pleural spaces, airways and lymph nodes [5]. Initial manifestations
include erythematous, violaceous cutaneous lesions (macular,
papular or nodular) involving the face, oral mucosa, and upper
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disease progresses [7]. CD4 counts are usually <200 cells/mm [3],
but more recent observation has shown an increased incidence of
KS at CD4  350 [4]. Patients with parenchymal lung involvement
may present with dyspnea, hypoxemia, or dry cough that develops
over weeks. In some cases, hemoptysis, fever, malaise and
respiratory failure may occur [13]. Pleural effusions can be seen
in up to two-thirds of patients with parenchymal KS and may be
the sole initial manifestation of the disease. Rapid progression of
pulmonary KS may occur in the setting of glucocorticoid use for
other conditions in HIV-infected patients [5,13].
Diagnosis of pulmonary KS is based on physical examination
ﬁndings, CT features, and characteristic endobronchial lesions [1].
Findings suggestive of KS on chest CT include hilar densities along
peribronchovascular pathways, and a nodular pattern along with
pleural effusions [8]. The diagnosis is conﬁrmed by typical
pathologic features such as inﬂammation, angiogenesis, spindle
cell proliferation and PCR or HHV-8 immunoassay on tissue biopsy
[7]. Seroprevalence of HHV-8 is 80–95% in patients with classic KS,
with HHV-8 detection via bronchoalveolar lavage in more than 80%
of patients with pulmonary KS [11]. Infection of endothelial cells
by HHV8 leads to expression of viral protein products, which
creates an angiogenic-inﬂammatory state. KS results from
proliferation of cells in response to this inﬂammatory state and
various angiogenic cytokines [6]. Development of KS is strongly
associated with defects in cellular immunity. Decreasing CD4
counts have shown to be associated with increasing risk of AIDS
associated KS [2].
Characteristic endobronchial lesions have a macular red or
purple appearance, and may be located at the airway bifurcations.
Diagnosis of pulmonary KS may be made presumptively if these
characteristic lesions are present along with radiologic ﬁndings,
and infection has been excluded [5]. If characteristic endobronchial
lesions are present, biopsy of these lesions is generally not
recommended as this may lead to pulmonary hemorrhage [12].
However, lung biopsy may be needed to make a deﬁnitive
diagnosis in cases when the clinical and radiological picture is
not typical [5]. Diagnosis is essential as pulmonary KS may mimic
infectious causes and treatment of these conditions differs. Our
patient did not have the characteristic endobronchial lesions and
bronchial biopsy established the diagnosis.
Treatment includes antiretroviral therapy with chemotherapy
reserved for patients with symptomatic pulmonary disease or
those with disease progression despite antiretroviral therapy [3].
Some patients with pulmonary KS have been treated with ART
alone and sustained an adequate response to treatment, while
others require chemotherapy [5]. Patients who have symptomatic
pulmonary involvement or evidence of disease progression despite
ART may beneﬁt from chemotherapy. First-line chemotherapy
agents for the treatment of KS include the anthracyclines –
liposomal doxorubicin and liposomal danorubicin [9]. Stebbing
and colleagues proposed a prognostic index for acquired immu-
nodeﬁciency syndrome (AIDS) associated KS, which includes four
factors: age, the occurrence of KS at or after AIDS onset, presence of
comorbid conditions, and immune status as marked by the CD4
count [14]. These widely used factors were incorporated into a
prognostic score calculation in a large study of 5873 patients. The
authors suggest that those with a high risk (score >12), should be
treated with ART and chemotherapy together, while those with a
low risk (score <5) may be given ART alone, with chemotherapy
considered if progression of disease occurs. However in some
cases, the systemic chemotherapy itself may be associated with a
higher morbidity. In severe cases, patients may be considered for
entry into clinical studies with newer agents [14]. Our patient had
poor prognostic factors and was not given chemotherapy due to
high risk for associated morbidity.In patients with endobronchial obstruction as a result of
pulmonary KS, therapy should be aimed at maintaining an
adequate airway and oxygenation. This may require endoscopic
laser resection, stent placement or radiation therapy [5,7]. Even
with the advent of ART and chemotherapy, pulmonary KS remains
an ominous diagnosis with a median survival of only 1.6 years. In
one large study of 1140 patients, ﬁve-year survival for patients
with pulmonary KS was 49% as compared to 82% for those with
classic KS [3,13].
Aboulaﬁ reported a frequency of 0–15% in patients with
pulmonary KS without mucocutaneous involvement, but rarely did
pulmonary KS present initially [1]. As this case illustrates,
pulmonary KS should be considered in patients with or at risk
for HIV infection who present with respiratory symptoms, even if
the typical mucocutaneous manifestations of KS or low CD4 cell
counts are absent. Patients with pulmonary KS may present with
shortness of breath, cough, chest pain, or less commonly,
hemoptysis. In certain cases, asymptomatic patients may have
abnormalities on CT scan characteristic of pulmonary KS such as
hilar densities along peribronchovascular pathways, and a septal
or nodular pattern with pleural effusions. The diagnosis of HIV
related pulmonary KS is often clinical: based on mucocutaneous
disease, suggestive ﬁndings on CT scan, and characteristic
endobronchial lesions. A detailed evaluation should be performed
to exclude other infectious causes or tumors. Our patient presented
with shortness of breath, but did not have these CT ﬁndings or
endobronchial lesions; lung biopsy was required to make the
deﬁnitive diagnosis.
Pulmonary KS should also be considered in the differential
when HIV-infected patients develop rapidly progressive respira-
tory symptoms after the initiation of glucocorticoid therapy.
Treatment with combination antiretroviral therapy is recom-
mended for all patients. For those with symptomatic pulmonary
involvement or evidence of disease progression despite ART,
chemotherapy should be considered. Early diagnosis and therapy
are essential in improving outcomes in this potentially deadly
disease.
Conﬂict of interest
The authors declare no conﬂict of interest.
Consent
Written informed consent was obtained from the patient for
publication of this case report and accompanying images. A copy of
the written consent is available for review by the Editor-in-Chief of
this journal on request.
References
[1] Aboulaﬁa DM. The epidemiologic, pathologic, and clinical features of AIDS-
associated pulmonary Kaposi’s sarcoma. Chest 2000;117(4):1128–45.
[2] Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and
severity of immunosuppression in persons with AIDS. J Natl Cancer Inst
2007;99(12):962–72.
[3] Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after
cancer diagnosis in persons with AIDS. J Acquir Immune Deﬁc Syndr
2005;39:293–9.
[4] Crum-Cianﬂone NF, Hullsiek KH, Ganesan A, Weintrob A, Okulicz JF, Agan BK,
et al. Is Kaposi’s sarcoma occurring at higher CD4 cell counts over the course of
the HIV epidemic? AIDS 2010;24:2881–3.
[5] Joshi M, Markelova N, Palacio D, Schapiro RM. A patient with HIV, dyspnea, and
multiple pulmonary nodules. Chest 2006;130:1924–8.
[6] Mesri EA. Inﬂammatory reactivation and angiogenicity of Kaposi’s sarcoma-
associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired
immunodeﬁciency syndrome-associated Kaposi’s sarcoma. Blood 1999;93:
4031–3.
T.F. Imran et al. / IDCases 1 (2014) 78–81 81[7] Miller RF, Tomlinson MC, Cottrill CP, Donald JJ, Spittle MF, Semple SJ. Bronch-
opulmonary Kaposi’s sarcoma in patients with AIDS. Thorax 1992;47(9):
721–5.
[8] Wolff SD, Kuhlman JE, Fishman EK. Thoracic Kaposi sarcoma in AIDS: CT
ﬁndings. J Comput Assist Tomogr 1993;17:60–2.
[9] Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, et al.
Randomized comparative trial of pegylated liposomal doxorubicin versus
bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma.
International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol
1998;16:683–91.[11] Howard M, Brink N, Miller R, Tedder R. Association of human herpes virus with
pulmonary Kaposi’s sarcoma. Lancet 1995;346:712.
[12] Pitchenik AE, Fischl MA, Saldana MJ. Kaposi’s sarcoma of the tracheobronchial
tree: clinical, bronchoscopic, and pathologic features. Chest 1985;87:122–4.
[13] Palmieri C, Dhillon T, Thirlwell C, Newsom-Davis T, Young AM, Nelson M, et al.
Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy.
HIV Med 2006;7(5):291–3.
[14] Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M, et al. A prognostic
index for AIDS-associated Kaposi’s sarcoma in the era of highly active antire-
troviral therapy. Lancet 2006;367:1495–502.
